2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M

2seventy bio, the cell therapy spinout of Bluebird bio, is selling itself to Bristol Myers Squibb after losing most of its market value in its short run as an independent biotechnology company.